abciximab [aapp, imft, phsu]
pharmacoeconomic [qnco]
Review [inpr]
Percutaneous [spco]
coronary revascularisation [topp]
abciximab [aapp, imft, phsu]
Monoclonal antibody [aapp, imft]
fragment [ftcn]
arrested [dsyn]
Platelet aggregation [celf]
antagonism [socb]
Glycoprotein IIb/IIIa [aapp, imft, rcpt]
Drug [phsu]
Heparin [bacs, carb, phsu]
Aspirin [orch, phsu]
PREVENT [phsu]
Ischaemic [ftcn]
Complications [patf]
Associated [qlco]
Percutaneous Coronary Revascularization [topp]
Patients [podg]
coronary heart disease [dsyn]
Large [qnco]
Well [qlco]
Design [acty]
Clinical Studies [resa]
Show [inpr]
abciximab [aapp, imft, phsu]
Aspirin [orch, phsu]
Heparin [bacs, carb, phsu]
To [qlco]
One [qnco]
Third [qnco]
One [qnco]
Half [qnco]
Incidence [qnco]
Ischaemic [ftcn]
Complications [patf]
days [tmco]
Percutaneous Coronary Revascularization [topp]
Drug [phsu]
APPEAR [qlco]
Patients [podg]
High Risk [qlco]
abciximab [aapp, imft, phsu]
Complications [patf]
Patients [podg]
coronary stenting [medd]
Drug [phsu]
Not [ftcn]
APPEAR [qlco]
To [qlco]
arrested [dsyn]
Restenosis [acab]
Tissue [tisu]
Stents [medd]
Long-term [tmco]
Benefit [qnco]
Reported [inpr]
Data [idcn]
Study [mnob]
Patients [podg]
Levels [qlco]
Risk Reduction [inbe]
Show [inpr]
Composite [qlco]
End Point [qlco]
Death [orgf]
Myocardial Infarction [dsyn]
Urgent [tmco]
Repeat [ftcn]
Revascularisation [topp]
Three [qnco]
Benefit [qnco]
Reported [inpr]
High Risk [qlco]
Patients [podg]
Meta-Analysis [inpr]
Result [ftcn]
Data [idcn]
Patients [podg]
Receive [qlco]
Stents [medd]
Show [inpr]
Reduced [qlco]
Mortality [qnco]
abciximab [aapp, imft, phsu]
abciximab [aapp, imft, phsu]
therapy [ftcn]
Incremental [qnco]
Cost [qnco]
standard therapy [topp]
Hospital [hcro, mnob]
Values [qlco]
months [tmco]
prospective [resa]
Economic [ocdi]
Major [qlco]
Clinical Trial [resa]
Drug [phsu]
High Risk [qlco]
Patients [podg]
abciximab [aapp, imft, phsu]
Cost [qnco]
Save [mcha]
Patients [podg]
Angina, Unstable [dsyn]
Mean [qnco]
Reticular [spco]
Cost [qnco]
Hospitalization [hlca]
Patients [podg]
Costs [qnco]
Show [inpr]
Further [spco]
Study [mnob]
Patients [podg]
Broad [spco]
Range [qnco]
Levels [qlco]
Risk [qlco]
OBSERVATIONAL [resa]
Data [idcn]
Reduced [qlco]
Duration [tmco]
Hospitalization [hlca]
abciximab [aapp, imft, phsu]
Cost Effectiveness [qnco]
Data [idcn]
abciximab [aapp, imft, phsu]
Aspirin [orch, phsu]
Heparin [bacs, carb, phsu]
month [tmco]
spanish [popg]
Dutch [popg]
Analysis [lbpr]
Data [idcn]
Above [spco]
Trial [resa]
Combined [qlco]
Local [spco]
Cost [qnco]
Data [idcn]
Not [ftcn]
australian [fndg]
Analysis [lbpr]
subgroup [virs]
Analysis [lbpr]
Indicated [fndg]
Enhanced [acty]
Cost Effectiveness [qnco]
High Risk [qlco]
Patients [podg]
Available [ftcn]
Data [idcn]
Show [inpr]
Clinical [qlco]
Benefit [qnco]
Cost Effectiveness [qnco]
abciximab [aapp, imft, phsu]
therapy [ftcn]
STENT, CORONARY [medd]
Placement [hlca]
Conclusions [idcn]
Data [idcn]
Intravenous infusion [topp]
Bolus [topp]
Plus [qlco]
regimens [inpr]
abciximab [aapp, imft, phsu]
Economically [ocdi]
Viable [qlco]
Patients [podg]
High [qlco]
Low Risk [fndg]
Ischaemic [ftcn]
Complications [patf]
Percutaneous Coronary Revascularization [topp]
Drug [phsu]
Show [inpr]
To [qlco]
Cost Effectiveness [qnco]
Patients [podg]
Receive [qlco]
Drug [phsu]
coronary stents [medd]
subgroup [virs]
Analysis [lbpr]
Additional [ftcn]
Cost Effectiveness [qnco]
Certain [qlco]
Group [idcn]
Patients [podg]
High Risk [qlco]
Ischaemic [ftcn]
Complications [patf]
Acute myocardial infarction [dsyn]
Angina, Unstable [dsyn]
